Literature DB >> 626671

The prostaglandin challenge. Test to unmask obstructed total anomalous pulmonary venous connections in asplenia syndrome.

R M Freedom, P M Olley, F Coceani, R D Rowe.   

Abstract

The patient with complex congenital heart disease, severe pulmonary outflow obstruction, and visceral heterotaxia, may have 'silent' obstruction of the pulmonary venous return. Severe reduction of pulmonary blood flow secondary to pulmonary stenosis or atresia in such patients may prevent the usual radiographic appearance of pulmonary oedema. If such obstructed anomalous pulmonary venous connections are not diagnosed before operation, construction of a systemic to pulmonary artery anastomosis will unmask the obstruction, usually resulting in pulmonary oedema and death. We have recently 'challenged' a neonate with dextrocardia, vesceral heterotaxia, presumed asplenia, and complex congenital heart disease including pulmonary atresia, with an infusion of prostaglandin E1 to increase pulmonary blood flow via his ductus arteriosus. This resulted in severe pulmonary oedema which partially resolved after the infusion was discontinued. This was interpreted as consistent with obstructed total anomalous pulmonary venous return. This was confirmed at necropsy. Thus, the infusion of prostaglandin E1 before operation in the patient with asplenia or similar cardiac disease may be of aid in unmasking 'silent' obstructions of the pulmonary veins, and is of obvious value in the preoperative assessment of such patients.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 626671      PMCID: PMC481981          DOI: 10.1136/hrt.40.1.91

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  14 in total

1.  SYNDROME OF CONGENITAL CARDIAC DISEASE WITH ASPLENIA. DISTINCTION FROM OTHER FORMS OF CONGENITAL CYANOTIC CARDIAC DISEASE.

Authors:  H D RUTTENBERG; H N NEUFELD; R V LUCAS; L S CAREY; P ADAMS; R C ANDERSON; J E EDWARDS
Journal:  Am J Cardiol       Date:  1964-03       Impact factor: 2.778

2.  The significance of asplenia in the recognition of inoperable congenital heart disease.

Authors:  W C ROBERTS; W B BERRY; A G MORROW
Journal:  Circulation       Date:  1962-12       Impact factor: 29.690

3.  Congenital absence of the spleen and associated anomalies.

Authors:  W G PUTSCHAR; W C MANION
Journal:  Am J Clin Pathol       Date:  1956-05       Impact factor: 2.493

4.  The symmetrical liver as a roentgen sign of asplenia.

Authors:  R V LUCAS; H N NEUFELD; R G LESTER; J E EDWARDS
Journal:  Circulation       Date:  1962-06       Impact factor: 29.690

5.  Successful total repair of complicated cardiac anomalies with asplenia syndrome.

Authors:  F Ando; H Shirotani; J Kawai; Y Kanzaki; N Setsuie
Journal:  J Thorac Cardiovasc Surg       Date:  1976-07       Impact factor: 5.209

6.  Editorial: Obstruction to pulmonary venous return obscured by decreased pulmonary blood flow.

Authors:  W M Gersony
Journal:  Chest       Date:  1973-09       Impact factor: 9.410

7.  Tetralogy of Fallot associated with total anomalous pulmonary venous drainage.

Authors:  A J Muster; M H Paul; H Nikaidoh
Journal:  Chest       Date:  1973-09       Impact factor: 9.410

8.  The response of the ductus arteriosus to prostaglandins.

Authors:  F Coceani; P M Olley
Journal:  Can J Physiol Pharmacol       Date:  1973-03       Impact factor: 2.273

9.  Further evidence implicating E-type prostaglandins in the patency of the lamb ductus arteriosus.

Authors:  P M Olley; E Bodach; J Heaton; F Coceani
Journal:  Eur J Pharmacol       Date:  1975-11       Impact factor: 4.432

10.  E-type prostaglandins: a new emergency therapy for certain cyanotic congenital heart malformations.

Authors:  P M Olley; F Coceani; E Bodach
Journal:  Circulation       Date:  1976-04       Impact factor: 29.690

View more
  10 in total

Review 1.  Obstructive total anomalous pulmonary venous drainage.

Authors:  A Nabar; B Dalvi
Journal:  Indian J Pediatr       Date:  1998 Jan-Feb       Impact factor: 1.967

2.  Outcome of infants with right atrial isomerism: is prognosis better with normal pulmonary venous drainage?

Authors:  Y F Cheung; V Y Cheng; A K Chau; C S Chiu; T C Yung; M P Leung
Journal:  Heart       Date:  2002-02       Impact factor: 5.994

3.  Management and outcome of infants and children with right atrial isomerism.

Authors:  M Sadiq; O Stümper; J V De Giovanni; J G Wright; B Sethia; W J Brawn; E D Silove
Journal:  Heart       Date:  1996-03       Impact factor: 5.994

4.  Total anomalous pulmonary venous drainage associated with tetralogy of Fallot: report of a case.

Authors:  L M Gerlis; G I Fiddler; R G Pearse
Journal:  Pediatr Cardiol       Date:  1983 Oct-Dec       Impact factor: 1.655

5.  Importance of totally anomalous pulmonary venous connection and postoperative pulmonary vein stenosis in outcomes of heterotaxy syndrome.

Authors:  Susan R Foerster; Kimberlee Gauvreau; Doff B McElhinney; Tal Geva
Journal:  Pediatr Cardiol       Date:  2007-11-15       Impact factor: 1.655

6.  Obstructed total anomalous pulmonary venous connection.

Authors:  J K Wang; H C Lue; M H Wu; M L Young; F F Wu; J M Wu
Journal:  Pediatr Cardiol       Date:  1993-01       Impact factor: 1.655

7.  Prostaglandin E1 in suspected ductus dependent cardiac malformation.

Authors:  K A Hallidie-Smith
Journal:  Arch Dis Child       Date:  1984-11       Impact factor: 3.791

8.  Surgical palliation of cardiac malformations associated with right isomerism.

Authors:  T Kawai; Y Wada; T Enmoto; S Nakajima; K Nishiyama; K Kitaura; S Sato; T Oka
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

9.  Responsiveness of the ductus arteriosus to prostaglandin E1 assessed by combined cross sectional and pulsed Doppler echocardiography.

Authors:  S Hiraishi; N Fujino; K Saito; K Oguchi; N Kadoi; Y Agata; Y Horiguchi; H Hozumi; K Yashiro
Journal:  Br Heart J       Date:  1989-08

10.  Ivemark syndrome: bronchial compression from anomalous pulmonary venous anatomy.

Authors:  Pooja H Patel; Joel Hayden; Randy Richardson
Journal:  J Surg Case Rep       Date:  2017-03-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.